After years of talking up artificial intelligence’s potential to help make drugs, Recursion will finally bring data to the table — and lots of it.
Sometime next month, the Salt Lake City-based biotech will share its first Phase 2 readout, starting a planned stretch of 10 trial readouts in 18…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
The recognition reflects eLuma’s dedication and commitment to the wellbeing of its employees and creating a people-first culture LEHI, Utah, Nov. 6, 2023 /PRNewswire-PRWeb/ — eLuma, an end-to-end student mental health and special education solution, […]
PARK CITY, Utah, Oct. 23, 2024 /PRNewswire/ — Globally recognized aesthetics device company Powered By MRP is pleased to announce the launch of MultiFrax, the first portable SimulScan 1550nm/1927nm laser, now available in the U.S. […]
“We’re in a frothy time,” acknowledges Alexandra Snyder, the head of R&D at Generate:Biomedicines. Generate is one of the AI-driven biotechs that make up a new generation of companies with huge funding, A-list science and […]
Copyright © 2026 Biotech Networks
